https://www.prnewswire.com/news-releases/abbvie-submits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis-301117875.html
AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis
– RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]
– In a pivotal Phase 2/3 study, twice as many patients receiving RINVOQ achieved the primary endpoint of ASAS 40 response at week 14 compared to placebo (p<0.001)[1] - A regulatory application was also submitted to the EMA for the treatment of adult patients with active ankylosing spondylitis earlier this year - This submission represents AbbVie's ongoing commitment to bringing RINVOQ to more patients living with immune-mediated diseases
